Beta Bionics Announces Third Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
Beta Bionics reported Q3 2026 net sales of $35.5 million, up 30% year-over-year, with pharmacy channel sales up 118% to $13.6 million and gross margin expanding 179 basis points to 57.3%. The company updated FY26 revenue guidance to $124-126 million but flagged up to $8.5 million of potential Q4 revenue deferral as prospective iLet users may wait for the Mint launch; it expects Mint to recapture those sales in 2027. Net loss widened to $24.4 million from $14.2 million a year ago, with adjusted EBITDA of negative $18.9 million, as sales-and-marketing and R&D spending scaled sharply.
Key figures
- Revenue
- 35505000
- Guidance
- FY26 revenue approximately $124 million to $126 million (previously $121 million to $126 million), with up to $8.5 million potential Q4 revenue deferral; gross margin 58.5%-59.5%
- Revenue Yoy
- 30%
- Net loss
- 24353000
- Gross margin
- 57.3%
- Operating loss
- 26609000
- Dme channel sales
- 21897000
- Pbp channel sales
- 13608000
- Pbp channel growth
- 118%
- Cash and investments
- 373600000
- Revenue deferral risk
- 8500000
- Net proceeds from offering
- 161300000
- Mint manufacturing capacity 2027
- 1.5 million disposable units
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.